Table 1 Clinical and molecular characteristics according to serum albumin levels in 214 glioblastoma cases
From: The prognostic role of preoperative serum albumin levels in glioblastoma patients
Clinical or molecular feature | All cases | Serum albumin levels | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
<30 g/L | ≥30 g/L | |||||||||
No. | % | No. | % | No. | % | |||||
Total no. of patients | 214 | 100 | 28 | 13.1 | 186 | 86.9 | ||||
Sex | ||||||||||
Male | 120 | 56.1 | 18 | 15 | 102 | 85 | 0.417 | |||
Female | 94 | 43.9 | 10 | 10.6 | 84 | 89.4 | ||||
Age, years | ||||||||||
Mean ± SD | 52.3 ± 12.8 | 52.3 ± 14.9 | 52.3 ± 12.6 | 0.995 | ||||||
Tumor size, cm 3 | ||||||||||
Mean ± SD | 62.9 ± 27.1 | 62.6 ± 26.8 | 63.0 ± 27.2 | 0.948 | ||||||
KPS | ||||||||||
Mean ± SD | 66.4 ± 13.7 | 58.2 ± 14.9 | 67.6 ± 13.1 | 0.001 | ||||||
Resection | ||||||||||
Biopsy | 15 | 7.0 | 2 | 13.3 | 13 | 86.7 | 0.960 | |||
Subtotal | 102 | 47.7 | 14 | 13.7 | 88 | 86.3 | ||||
Gross total | 97 | 45.3 | 12 | 12.4 | 85 | 87.6 | ||||
Adjuvant treatment | ||||||||||
NAG | 58 | 27.1 | 13 | 22.4 | 45 | 77.6 | 0.004 | |||
PAG | 77 | 36.0 | 12 | 15.6 | 65 | 84.4 | ||||
CAG | 79 | 36.9 | 3 | 3.8 | 76 | 96.2 | ||||
MGMT promoter | ||||||||||
Methylated | 99 | 46.3 | 16 | 16.2 | 83 | 83.8 | 0.229 | |||
Unmethylated | 115 | 53.7 | 12 | 10.4 | 103 | 89.6 | ||||
IDH1 R132H mutation | ||||||||||
Positive | 14 | 6.5 | 3 | 21.4 | 11 | 78.6 | 0.338 | |||
Negative | 200 | 93.5 | 25 | 12.5 | 175 | 87.5 | ||||
Prealbumin, mg/L | ||||||||||
Mean ± SD | 247.0 ± 51.2 | 224.1 ± 36.7 | 250.5 ± 52.2 | 0.011 | ||||||
Total protein, g/L | ||||||||||
Mean ± SD | 61.2 ± 7.0 | 58.8 ± 5.7 | 61.6 ± 7.1 | 0.052 | ||||||
TLC, 10 9 /L | ||||||||||
Mean ± SD | 1.8 ± 0.8 | 1.7 ± 0.8 | 1.8 ± 0.7 | 0.302 | ||||||